Skip Navigation LinksHome > February 2013 - Volume 33 - Issue 1 > Comparison of Treatment Response in Second-Episode Versus Fi...
Journal of Clinical Psychopharmacology:
doi: 10.1097/JCP.0b013e31827bfcc1
Brief Reports

Comparison of Treatment Response in Second-Episode Versus First-Episode Schizophrenia

Emsley, Robin MD*; Oosthuizen, Petrus MD*; Koen, Liezl MD*; Niehaus, Dana MD*; Martinez, Lupe MD

Supplemental Author Material
Collapse Box

Abstract

Abstract: This study investigated whether illness progression and treatment refractoriness emerge after relapse in schizophrenia. We compared outcomes in a cohort treated with a standardized protocol for the first and second episodes of illness. The sample comprised 31 participants who (1) had successfully completed a 2-year open-label treatment phase with risperidone long-acting injection (RLAI) for a first episode of schizophrenia; (2) underwent an intermittent treatment extension phase up to 3 years or until recurrence, and (3) entered a further 2-year treatment phase with RLAI for a recurrence episode. For the patients who remained in treatment (n = 14 [45%]), Positive and Negative Syndrome Scale score reductions, response rates, remission rates, time to response, time to remission, functional outcome scores, and modal RLAI doses were similar for the 2 treatment periods. However, 17 (55 %) of the 31 patients discontinued the study in the second episode compared with 14 (28%) of 50 patients in the first episode, suggesting reduced effectiveness of antipsychotics when reintroduced after illness recurrence. Most notably, emergent treatment nonresponsiveness was observed in 5 participants (16%), consistent with the hypothesis that relapse may be biologically harmful in a subset of patients.

© 2013 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.